PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
May 10, 2026SLEEP

1001 Intersection of Obstructive Sleep Apnea and Treatment Resistant Hypertension

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Although OSA treatment shows modest blood pressure effects overall, evidence suggests increased benefits in treatment-resistant hypertension, prompting characterization of patients newly diagnosed with OSA and comorbid TRH.

Population

843 adults with newly diagnosed OSA and comorbid TRH

Design

Retrospective administrative claims study

Key result

Patients with newly diagnosed obstructive sleep apnea and comorbid treatment-resistant hypertension exhibited a high comorbidity burden, including hyperlipidemia (70%) and type 2 diabetes (40%).

Authors

AMAnil K. MalhotraRDR DexterCWCaleb Woodford

Discussion

Loading...

Member takes

Overview

High hyperlipidemia burden in sleep patients merits clinical attention; leaves open causality and value of integrated therapy in trials.

Key Points

  • This study aims to describe the demographics and clinical characteristics of patients with obstructive sleep apnea (OSA) and treatment-resistant hypertension (TRH).
  • Retrospective analysis of administrative claims data from commercial, Medicaid, and Medicare Advantage plans for patients newly diagnosed with OSA between October 2024 and May 2025.
  • Inclusion of adults with a diagnosis code for TRH in the year prior to their OSA diagnosis, requiring ≥1 year of data prior to the sleep test.
  • Identification of comorbidities and prescription fills using ICD-10 diagnosis codes and NDC codes.
  • A total of 843 patients met inclusion criteria (47% female, mean age: 53 years).
  • 70% of patients had either obesity or severe obesity, with a high burden of comorbid conditions averaging 3.5 other conditions.
  • Common cardiometabolic conditions included hyperlipidemia (70%), type 2 diabetes (40%), coronary artery disease (26%), and significant mental health issues, especially in women.

Study Design

Type

Observational (n=843)

Structured PICO

P
Population
843 adults (≥18 years) with newly diagnosed obstructive sleep apnea (OSA) and comorbid treatment-resistant hypertension (TRH), mean age 53 years, 47% female.
O
Outcome
Demographics and clinical characteristics (comorbidities and prescription fills)

Patients with newly diagnosed OSA and comorbid treatment-resistant hypertension have a high burden of cardiometabolic and psychological comorbidities, highlighting the need for comprehensive screening and management.

Cite This Study

Malhotra et al. (2026) conducted an observational in Obstructive sleep apnea and treatment-resistant hypertension (n=843). Patients with newly diagnosed obstructive sleep apnea and comorbid treatment-resistant hypertension exhibited a high comorbidity burden, including hyperlipidemia (70%) and type 2 diabetes (40%).

synapsesocial.com/papers/6a0021e6c8f74e3340f9ce63https://doi.org/10.1093/sleep/zsag091.1000
View Full Paper
Ask AI
Bookmark
Share